Shares of Tokai Pharmaceuticals Inc (NASDAQ:TKAI) ended Monday session in green amid volatile trading. The shares closed up +0.09 points or 7.20% at $1.34 with 22.63 million shares getting traded. Post opening the session at $1.28, the shares hit an intraday low of $1.28 and an intraday high of $1.47 and the price vacillated in this range throughout the day. The company has a market cap of $29.62 million and the numbers of outstanding shares have been calculated to be 22.63 million shares.
Tokai Pharmaceuticals Inc (TKAI), a biopharmaceutical company, focuses on developing and commercializing therapies for prostate cancer and other hormonally-driven diseases. Its lead drug candidate is galeterone, an oral small molecule that is in various clinical trials for the treatment of patients with metastatic castration-resistant prostate cancer. The companys androgen receptor degradation (ARDA) drug discovery program is focused on identifying and developing compounds for ARDA activity. Tokai Pharmaceuticals, Inc. was founded in 2004 and is based in Boston, Massachusetts.
Shares of Endo International plc – Ordinary Shares (NASDAQ:ENDP) ended Monday session in red amid volatile trading. The shares closed down -0.79 points or -3.79% at $20.06 with 222.77 million shares getting traded. Post opening the session at $20.86, the shares hit an intraday low of $20.05 and an intraday high of $20.96 and the price vacillated in this range throughout the day. The company has a market cap of $4.64 billion and the numbers of outstanding shares have been calculated to be 222.77 million shares.
Endo International plc – Ordinary Shares (ENDP) develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. Branded Pharmaceuticals segment offers chronic pain management products, such as BELBUCA, OPANA ER, and Percocet; Lidoderm for opioid analgesics; and Voltaren gel for osteoarthritis pain, as well as XIAFLEX for treating Peyronies and Dupuytrens contracture diseases. This segment also provides Supprelin LA for central precocious puberty treatment; testosterone replacement therapies, such as Aveed and TESTOPEL, as well as Fortesta and Testim gels; Frova and Sumavel DosePro for migraine headaches; Valstar, a sterile solution for intravesical instillation of valrubicin; and Vantas for the palliative treatment of prostate cancer.